We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC APPROVES TEVA-BMS GENERIC PARAPLATIN DISTRIBUTION DEAL
FTC APPROVES TEVA-BMS GENERIC PARAPLATIN DISTRIBUTION DEAL
May 25, 2004
The FTC has signed off on a deal between Bristol-Myers Squibb (BMS) and Teva Pharmaceutical that will give Teva nearly a four-month jump on launching a generic version of BMS’ cancer drug Paraplatin.